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Background: Previous economic analyses evaluating treatment of methicillin-resistant 
 Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTI) failed to 
include all direct treatment costs such as outpatient parenteral antibiotic therapy (OPAT). Our 
objective was to develop an economic model from a US payer perspective that includes all 
direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, 
vancomycin, or daptomycin.
Methods: A 4-week decision model was developed for this economic analysis. Published 
literature and database analyses with validation by experts provided clinical, resource use, and 
cost inputs on data such as efficacy rate, length of stay, adverse events, and OPAT services. 
Base-case analysis assumed equal efficacy and equal length of stay for treatments. We conducted 
several sensitivity analyses where assumptions on resource use or efficacy were varied. Costs 
were reported in year-end 2011 US dollars.
Results: Total treatment costs in the base-case were lower for linezolid ($10,571) than 
vancomycin ($11,096), and daptomycin ($13,612). Inpatient treatment costs were $740 more, 
but outpatient costs, $1,266 less with linezolid than vancomycin therapy due to a switch to 
oral linezolid when the patient was discharged. Compared with daptomycin, both inpatient 
and outpatient treatment costs were lower with linezolid by $87 and $2,954 respectively. In 
sensitivity analyses, linezolid had lower costs compared with vancomycin and daptomycin 
when using differential length of stay data from a clinical trial, and using success rates from a 
meta-analysis. In a scenario without peripherally inserted central catheter line costs, linezolid 
became slightly more expensive than vancomycin (by $285), but remained less costly than 
daptomycin (by $2,316).
Conclusion: Outpatient costs of managing MRSA cSSTI may be reduced by 30%–50% with 
oral linezolid compared with vancomycin or daptomycin. Results from this analysis support 
potential economic benefit and cost savings of using linezolid versus traditional OPAT when 
total inpatient and outpatient medical costs are evaluated.
Keywords: economic model, OPAT, cost
Introduction
Treatment guidelines recently released by the Infectious Diseases Society of America 
for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) skin and 
soft-tissue infections (SSTI) list several options for treating hospitalized patients 
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with complicated MRSA SSTI.1 Treatment recommenda-
tions based on evidence from one or more randomized, 
controlled studies include intravenous and oral linezolid 
and intravenous vancomycin, daptomycin, or telavancin 
for 7–14 days.
Linezolid, in comparison with these other recommended 
treatments, is 100% bioavailable when administered orally, 
meaning the same linezolid dosing regimen is used for 
intravenous and oral administration.2 The benefits of oral 
compared with intravenous administration are numerous 
and include decreased intravenous administration costs, 
intravenous line infections, length of hospital stay, and 
increased patient convenience.3,4
Results from clinical studies and meta-analyses show that 
linezolid is at least as effective as vancomycin or daptomycin 
in treating patients with MRSA SSTI.5–10 Patients prescribed 
linezolid compared with vancomycin for documented or 
presumed MRSA SSTI receive fewer days of intravenous 
therapy7,11–13 and have shorter hospital stays.7,9,11–15
In the year 2007, an estimated 570,000–600,000 patients 
in the US were hospitalized and discharged with a principal 
diagnosis of an SSTI;16 the inpatient length of stay was 
approximately 4.5 days.16 Results from data submitted to 
the SENTRY Antimicrobial Surveillance Program for the 
year 2004 show that S. aureus (51.6%) is the most common 
cause of SSTI in North America; oxacillin resistance is 
reported in 47.4% of S aureus isolates.17 Based on these data, 
approximately 135,500–146,750 patients are hospitalized and 
receive a primary diagnosis of MRSA SSTI in the United 
States annually.
Although the societal and economic costs of treating MRSA 
SSTI are currently unknown, the current health care climate 
demands utilization of the most cost-effective therapies in 
both the inpatient and outpatient settings. Costs that should be 
included in an overall evaluation of treatment strategy include 
not only drug acquisition costs, but also costs incurred for 
hospital room and board, drug administration and preparation, 
diagnostic and laboratory testing, and drug-related adverse 
events or allergic reactions.18 Study results show that the total 
cost of vancomycin therapy excluding room and board is three 
to four times higher than vancomycin acquisition cost.19
Several studies evaluated the economic effect of linezolid 
compared with vancomycin on the treatment of patients 
with MRSA complicated SSTI (cSSTI) from various 
perspectives.9,12,13,20–23 Linezolid was more cost-effective than 
vancomycin therapy for the treatment of patients with MRSA 
cSSTI in the majority of studies.9,12,13,21–23
Daptomycin is an intravenous therapy recommended1 and 
frequently used for MRSA cSSTI. Very few studies have been 
conducted on its economic comparison with vancomycin 
and/or linezolid.24,25 In studies that were reviewed, daptomycin 
was found cost-effective compared with vancomycin, but not 
versus linezolid.42
None of these studies, however, included all costs 
incurred by patients with MRSA cSSTI initially treated as 
a hospital inpatient and eventually treated as an outpatient 
for the remaining duration of therapy. Specifically, in many 
studies, the additional medical costs related to outpatient 
administration of parenteral vancomycin or daptomycin 
therapy were not included. Therefore, we conducted a 
pharmacoeconomic analysis to assess and compare the value 
of linezolid, vancomycin, and daptomycin in the treatment of 
MRSA cSSTI from a US third-party payer’s perspective using 
a decision analytic model. Our model uniquely includes the 
cost components of outpatient antibiotic treatment incurred 
by patients with MRSA cSSTI treated with either intravenous 




A decision tree was constructed based on information 
from clinical trials and other published literature such 
as retrospective database analyses. When gaps existed 
in the literature or when the literature information was 
contradictory or uncertain, it was complemented by 
assumptions from a panel of infectious disease physicians 
and a homecare intravenous therapy nurse. The model was 
developed using Microsoft Excel and Visual Basic.
The perspective of this analysis is that of US third-party 
payers. Our model includes direct medical costs only. 
A distinction was made between inpatient and outpatient 
costs. Inpatient costs include general ward, specialist, adverse 
event, and drug costs; outpatient costs include outpatient 
parenteral antibiotic therapy (OPAT), physician office visit, 
and peripherally inserted central catheter (PICC) placement 
and complication costs.
Model population
Our model population was equivalent to the population 
included in a linezolid Phase 4 study,7 and consisted of 
patients with various MRSA cSSTI such as surgical wound 
infections, traumatic wound infections, abscesses, other 
acutely infected ulcers, infected burn wounds (,20% body 
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surface area), infected diabetic ulcers, and other cSSTIs 
requiring systemic antimicrobial therapy.
Model structure
Patients enter the model following diagnosis of a 
suspected or proven Gram-positive cSSTI (Figure 1). 
The model timeframe was 4 weeks to encompass the time 
needed for inpatient, outpatient, and second-line treatment 
of a Gram-positive cSSTI. The patient was initially treated 
for 2 days empirically (an average time per expert opinion 
that may be required to have culture and sensitivity results 
available from the laboratory) as a hospital inpatient with 
either vancomycin or cefazolin until confirmatory laboratory 
results were obtained. Hence, during this empiric treatment 
phase, 2 days of hospitalization costs and empiric drug 
treatment costs were generated. Following laboratory 
confirmation of MRSA cSSTI, patients received linezolid, 
vancomycin, or daptomycin for an additional 12 days.1,26 The 
total length of empiric and definitive antibiotic treatment 
was 14 days.1,10
Subsequently, treatment can succeed, fail, or cause 
an adverse event leading to drug discontinuation. If the 
treatment succeeded, the patient received that one 14-day 
course of antibiotic treatment. If the treatment failed or 
was discontinued due to an adverse event, linezolid and 
vancomycin patients were switched to second-line daptomycin, 
and first-line daptomycin patients to second-line linezolid 
therapy based on expert opinion that if patients were failing 
initial therapy they would not be switched to vancomycin, 
but rather a newer agent with better tissue penetration. 
Economic consequences for patients failing f irst-line 
therapy or discontinuing first-line therapy due to an adverse 
event were 5 additional days of hospital stay27 and second-
line drug therapy for 14 days.1
Model inputs
The model’s clinical inputs and resource use components 
are outlined in Table 1.
Clinical inputs
Drug efficacy was estimated from a randomized, open-label, 
controlled, multicenter, Phase 4 study (trial 1002) which 
compared linezolid with vancomycin therapy in patients with 
MRSA-confirmed cSSTI.7 The difference in clinical response 
at end of treatment between linezolid- and vancomycin-
treated patients in this study was not statistically  significant. 
 Therefore, the linezolid and vancomycin results were pooled, 
and a weighted average efficacy rate of 89.5% was utilized.28 
Noninferiority of daptomycin to comparator drugs (mainly 
vancomycin) has been reported in the daptomycin product 
label, thus for the base-case analysis, we assumed that 
daptomycin would have similar efficacy to vancomycin and 
linezolid. A meta-analysis for MRSA cSTTI was later used in 
sensitivity analyses of the model which provided differential 
efficacy rates.8
We assumed that the remaining 10.5% of patients were 
switched to daptomycin or linezolid second-line therapy1 
due to treatment failure with first-line therapy or in the case 
of an adverse event requiring treatment discontinuation. All 
patients were assumed to successfully finish second-line 
therapy, an assumption also made by others.20 At the end of 
our 4-week model, all patients were assumed cured.
 2 days
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Figure 1 Model structure.
Abbreviations: cSSTI, complicated skin and soft tissue infection; AE, adverse events; MRSA, methicillin-resistant Staphylococcus aureus.
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Resource inputs
In our model, we distinguished between resources used for 
empiric, first-line, and second-line treatments. Resources 
included in the model are the following:
•	 Days of antibiotic treatment
•	 Days of intravenous therapy
•	 Hospital stay: general ward
•	 Infectious disease specialist visits
•	 Physician office visits
•	 Outpatient laboratory tests
•	 Days of OPAT homecare
•	 Infusion center visits (for patients not receiving OPAT in 
the home)
•	 PICC placement and complications.
All patients received antibiotic therapy for a minimum 
of 14 days, which included initial empiric treatment for 
2 days (while waiting for culture results) followed by first-
line treatment for 12 days. Empiric treatment assumed in 
the model was either intravenous vancomycin 1 g every 
12 hours or cefazolin 1 g every 8 hours. First-line treatments 
in the model were either 2 days of inpatient and 10 days 
of outpatient intravenous vancomycin 1 g every 12 hours, 
or 2 days of inpatient intravenous linezolid 600 mg every 
12 hours followed by 10 days of outpatient oral linezolid 
600 mg every 12 hours, or 2 days of inpatient and 10 days 
outpatient intravenous daptomycin 4 mg/kg (300 mg for 
75 kg patient) every 24 hours.
All patients were assumed treated as a hospital inpatient for 
4.5 days based on the Healthcare Cost and Utilization Project 
data.16 This length of stay value was chosen over the global 
trial length of stay data (7.6 days linezolid versus 8.9 days 
vancomycin) because the trial data represented a mix of 
countries. In regional analyses of the trial data, the US-specific 
data also suggested a length of stay of ∼5 days,29 thus confirming 
the nationally representative data. The hospital stay was 
assumed to be in a general ward. Patients receiving linezolid 
were switched from intravenous to oral therapy at hospital 
discharge. Patients receiving vancomycin or daptomycin were 
discharged home through an OPAT program.
Resource utilization was also attached to treatment failures 
and adverse events that resulted in drug discontinuation. 
Results from clinical studies suggested that drug failures 
and discontinuations due to adverse events would not differ 
substantially between the treatment arms.5,7,9,10 Additional 
resources for treatment of drug failures and adverse events 
resulting in drug discontinuation were deemed equal to the 
cost of five additional hospital days28 plus the cost of 14 days 
of second-line therapy. We assumed that each patient would 
Table 1 Model input data














 Success, % 100 100 100 Assumption
Resource inputs
Hospital stay, days 4.5 4.5 4.5 Barrett et al16
Hospital stay due to failure or 
discontinuation, additional daysb
5 5 5 Edelsberg et al27
Empiric antibiotic therapy, days 2 2 2 De Cock et al,21 Schurmann et al23
Definitive antibiotic therapy, days
 IV therapy, days










Weigelt et al,10 Liu et al1
Intravenous doses per day 2 2 1 Product label,2 Tice46
Oral doses per day 2 0 0 Product label2
ID physician inpatient visits 1 1 1 Tice et al,43 assumption
ID physician office visits 1 1 1 Tice et al,43 assumption
Outpatient laboratory work 1 1 1 Tice46
Outpatient parenteral  
antibiotic days
0 9.5 9.5 Calculated from above, also
consistent with Itani et al7
PICC placement 0 1 1 Tice46
PICC complications 0 1c 1c Tice et al,31 Moureau et al30
Notes: aAssumed to be same as linezolid/vancomycin for the base-case analysis; no direct trial comparison with linezolid and daptomycin; bdiscontinuation due to adverse 
event; cPICC complication costs will be added to all patients undergoing PICC placement. These costs are further detailed in Table 2.
Abbreviations: ID, infectious disease; IV, intravenous; PICC, peripherally inserted central catheter.
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require one infectious disease specialist consult during their 
inpatient stay. Vancomycin arm adverse events were assigned 
in the empiric phase of treatment and not again in the MRSA-
confirmed phase of treatment. This was an assumption in 
favor of vancomycin, as patients assigned to the linezolid or 
daptomycin arm received vancomycin adverse event costs in 
the empiric phase, as well as linezolid/daptomycin adverse 
event costs in the definitive treatment phase.
Outpatient resource use was based on the published 
literature30–33 and supplemented with expert opinion when 
necessary for resource items such as frequency of outpatient 
visits (ie, all patients were expected to require one outpatient 
follow-up visit with a physician). Outpatient parenteral 
antibiotic therapy and a PICC line were required by patients 
receiving vancomycin or daptomycin, while linezolid patients 
received oral therapy as an outpatient.
Cost inputs
Wholesale acquisition price was utilized for drug costs 
(Table 2).34 Medical care resource unit costs were retrieved 
from the published literature30,32,33,35 and estimated based on 
current procedural terminology codes and corresponding fee 
schedules (Table 2).36 If needed, costs were adjusted to 2011 
US dollars using the medical component of the Consumer 
Price Index.37
Model assumptions
As information from the literature was lacking in several areas, 
the following assumptions were made that were subsequently 
verified by interviews with an infectious disease physician 
specializing in OPAT and a homecare intravenous therapy 
nurse familiar with OPAT. In some cases, the assumptions 
were also utilized in other pharmacoeconomic analyses:
•	 Empiric treatment was with either vancomycin (50% of 
cases) or cefazolin (50% of cases) while culture results 
were pending.
•	 Culture results confirming MRSA were obtained after 
2 days of empiric treatment,23 at which point definitive 
treatment could be established with either linezolid, 
vancomycin, or daptomycin.
Table 2 Cost inputs
Cost inputs Cost adjusted to 
2011 (US$)a
Data source
Drug costs (wholesale acquisition cost per dose)
Linezolid IV 600 mg $107.10 First DataBank, Inc34
Linezolid oral 600 mg $89.39 First DataBank, Inc34
Vancomycin IV 1 g $5.79 First DataBank, Inc34
Cefazolin IV 1 g $2.19 First DataBank, Inc34
Daptomycin IV 300 mg (500 mg vial used) $256.29 First DataBank, Inc34
Injection costs per dose $7.21 Tice et al33
Medical costs
General ward, per day $1,348.50 Candrilli and Mauskopf35
ID specialist, inpatient visit $231.95 CPT 99253, inpatient consult, 50th percentile, Ingenix36
Physician outpatient visit $222.40 CPT 99215, office visit, 50th percentile, Ingenix36
Laboratory tests, vancomycin $101.06 CPT 80069 renal function $64.92 + CPT 80202 
vancomycin level $36.14, Ingenix36
Laboratory tests, linezolid $34.34 CPT 85025 – complete blood count, Ingenix36
OPAT daily cost $193.67 Tice et al32 (fee-for-service with medication related 
costs removed)
PICC placement $656.80 CPT 36569 for placement $561.58 + CPT 71010 for 
X-ray $95.22, 50th percentile, Ingenix36
PICC complication cost per patient
• Physician visit
• Declotting procedure with CathFlo
• Emergency room visit
• Rehospitalization
•  PICC replacement including chest X-ray
$153.81
•  17% (Tice et al31) @ CPT 99215, $222.40 (Ingenix36)
•  7% (Tice et al31) @ CPT 36593 $199.66 (Ingenix36) 
and drug cost $106.33 (First DataBank34)
•  2% (Moureau et al30) @ CPT 99284 $380.40 
(Ingenix36) + facility fees of $222.58
•  1% (Moureau et al30) @ DRG 920 $5,114.60 (2008 
Median cost from HCUP adjusted to US$ 2011)
•  5% (Moureau et al30) @ CPT 36584 $532.42 + CPT 
71010 $95.22 (Ingenix36)
Notes: aDrug prices reported as wholesale acquisition costs 2011, all other costs adjusted to 2011 US$.
Abbreviations: IV, intravenous; ID, infectious disease; OPAT, outpatient therapy; PICC, peripherally inserted central catheter; CPT, current procedural terminology; DRG, 
diagnosis-related group; HCUP, Healthcare Cost and Utilization Project.
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•	 Second-line treatment was administered for 14 days and 
was assumed to be effective.20
•	 Resource use associated with drug failure or adverse 
events resulting in drug discontinuation was similar 
between all treatment arms.
•	 Every patient survives during the period of antibiotic 
treatment.20 Furthermore, the Itani trial7 mortality rates 
were ,1% and did not differ between treatments, thus 
mortality was not included in the analysis.
Base-case analysis
We conducted a cost-minimization analysis using our base-
case data because no difference in efficacy was assumed. 
Total direct medical costs across the 4-week period were 
calculated for each drug. Additionally, we disaggregated 
costs by care setting (inpatient or outpatient), cost type (drug-
related or medical), and resource component (eg, hospital 
stay, physician visits, PICC placement).
Sensitivity analyses
We conducted several scenario-based sensitivity analyses 
in which the assumptions for resource use or efficacy were 
varied. Scenarios were identified related to the variables 
found to have greatest influence on overall results.
Scenario 1: trial-based length of stay
In the first scenario, we altered length of stay by incorpo-
rating data from a Phase 4 study comparing linezolid with 
vancomycin therapy in patients with MRSA cSSTI.7 This 
scenario utilized a differential length of stay of 7.6 days for 
linezolid-treated patients and an 8.9-day length of stay for 
vancomycin and daptomycin (assumed to be similar to van-
comycin) treated patients. In the base-case analysis, length 
of stay was 4.5 days for patients on all treatments.
Scenario 2: PICC costs excluded
In the second scenario, we excluded PICC placement costs 
and their associated complications. In an effort to capture the 
full cost of outpatient vancomycin or daptomycin therapy, we 
included PICC costs in our base-case model; to our knowl-
edge, this is the only published economic study where such 
treatment comparisons for MRSA cSSTI include PICC cost 
data, therefore this sensitivity analysis evaluated the impact of 
use of PICC lines on economic outcomes related to OPAT.
Scenario 3: efficacy rates from meta-analysis
In the final scenario we incorporated efficacy rates from 
a Bayesian meta-analysis8 into our model. Results from 
this meta-analysis suggested different efficacy rates for 
patients receiving linezolid (84.4%) compared with van-
comycin (74.7%) or daptomycin (78.1%) for treatment of 
MRSA cSSTI. Thus, for this scenario we performed a cost-
effectiveness analysis which incorporated quality-of-life 
assumptions. Differences in costs and quality-adjusted life 
years (QALYs) were determined. Utility values were not 
identified in the published literature for cSSTI. Therefore, 
we used proxies from diabetic foot infection, dermatologic 
disease, and other infections to estimate utility values.38–40 
Utilities included in the current model were MRSA infec-
tion (0.44),40 treatment success (1, assumption), treatment 
failure (0.93),39 and drug discontinuation due to an adverse 
event (0.93).38 If a patient suffered from multiple health 
events at the same time, the corresponding utility values were 
calculated using the multiplicative method. For example, 
if a patient with an MRSA infection also experienced an 
adverse event resulting in drug discontinuation, the utility 
value was 0.44 × 0.93 = 0.41.
Results
Base-case analysis
The total cost per patient was US$10,571 for linezolid, 
US$11,096 for vancomycin, and US$13,612 for daptomycin 
treatment in the base-case analysis (Table 3). Treatment 
costs were lower by US$526 and US$3,042 per patient 
over the 4-week model timeframe for patients who received 
linezolid compared with vancomycin and daptomycin 
respectively.
Analysis by site of care showed higher inpatient treat-
ment costs with daptomycin and linezolid (US$7,922 and 
US$7,835 respectively) compared with vancomycin therapy 
(US$7,095). The higher inpatient linezolid and daptomycin 
treatment costs resulted from increased drug acquisition 
costs. In contrast, outpatient treatment costs were lower with 
linezolid (US$2,736) compared with vancomycin (US$4,001) 
and daptomycin (US$5,690) therapy, resulting from lower 
outpatient medical costs, specifically OPAT, PICC line, and 
laboratory costs.
Similarly, analysis by cost type found that total drug costs 
were US$1,958 higher but medical costs were US$2,484 
lower with linezolid compared with vancomycin therapy. 
For daptomycin, both drug and medical costs were higher 
than linezolid and vancomycin. Once again, this decrease in 
medical costs for linezolid was derived from lower OPAT, 
PICC, and laboratory costs. Overall, outpatient medical costs 
were fivefold lower with linezolid than with vancomycin or 
daptomycin therapy.
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Sensitivity analyses
Scenario 1: trial-based length of stay
In this scenario, the total cost per patient for linezolid treat-
ment was US$14,906 compared with US$16,178 for vanco-
mycin and US$18,694 for daptomycin (Table 4). Linezolid 
compared with vancomycin and daptomycin treatment saved 
US$1,272 and US$3,788, respectively, per patient over the 
4-week model timeframe. The cost savings realized with 
linezolid therapy in this scenario were greater than in the 
base-case analysis. This additional cost savings resulted 
from a decrease in inpatient medical costs primarily due 
to a decrease in length of stay for linezolid compared with 
vancomycin- or daptomycin-treated patients.
Scenario 2: PICC costs excluded
In this scenario, the total cost per patient for linezolid treat-
ment was US$10,486, just slightly higher than the cost for 
vancomycin (US$10,201), but still substantially lower than 
daptomycin therapy (US$12,802) (Table 4). Thus, in some 
cases where a patient did not require a PICC line for vanco-
mycin administration, linezolid therapy costs were similar 
to those of vancomycin: approximately US$285 more per 
patient over the 4-week model timeframe.
Scenario 3: efficacy rates from meta-analysis
In this scenario linezolid treatment was dominant, having 
more QALYs gained and a lower treatment cost compared 
with vancomycin and daptomycin treatment (Table 4). 
Gains in QALYs were very small due to the short model 
timeframe, and were higher for linezolid-treated patients by 
0.002 QALYs and 0.001 QALYs compared with vancomy-
cin and daptomycin respectively. Similarly, treatment costs 
were lower for linezolid compared with vancomycin and 
daptomycin (Table 4).
An assessment of the detailed cost breakdown indicated 
that the most influential model variables were success rate, 
followed by length of hospital stay, OPAT costs, and PICC 
line utilization and complications. These were the scenarios 
presented in Table 4. Drug prices and OPAT costs would be 
sensitive by definition as well; however, these would be fixed 
for a given health care system.
Discussion
The aim of our economic model was to provide a flexible 
framework capable of assessing and comparing the value 
of intravenous/oral linezolid, intravenous vancomycin, 
Table 3 Base-case analysis results








Total inpatient costs $7,835 $7,095 $7,922
 Inpatient drug costs $626 $119 $713
  Drug treatment $554 $47 $659
  Drug administration $72 $72 $54
 Inpatient medical costs $7,209 $6,976 $7,209
  Hospital days $6,068 $6,068 $6,068
  ID specialist $232 $232 $232
  Adverse event costsa $435 $201 $435
  Failure costs $474 $474 $474
Total outpatient costs $2,736 $4,001 $5,690
 Outpatient drug costs $2,086 $634 $2,766
  Drug treatment $2,075 $487 $2,698
  Drug administration $11 $148 $68
 Outpatient medical costs $650 $3,367 $2,924
  Physician visit $246 $246 $246
  Laboratory work $34 $101 $28
  OPAT costb $285 $2,125 $1,840
   PICC line and  
complicationsb
$85 $896 $811
Total cost of treatment $10,571 $11,096 $13,612
 Total drug costs $2,712 $754 $3,479
 Total medical costs $7,859 $10,343 $10,133
Notes: Costs may not tally due to rounding. aAdverse event costs are higher for 
linezolid and daptomycin arm because they are assigned the vancomycin adverse 
event costs from empiric treatment plus any linezolid/daptomycin adverse event 
costs. Vancomycin is only assigned adverse event costs once; bOPAT and PICC line 
costs are incurred in the linezolid arm through treatment failures and switching to 
other IV antibiotics.
Abbreviations: ID, infectious disease; OPAT, outpatient parenteral antibiotic 
therapy; PICC, peripherally inserted central catheter; IV, intravenous.
Table 4 Scenario-based sensitivity analyses






Scenario 1, trial-based length of stay7
 Linezolid, 7.6 days
 Vancomycin and daptomycin, 8.9 days
$14,906 $16,178 $18,694
Scenario 2, no PICC line costs $10,486 $10,201 $12,802
Scenario 3, meta analysis efficacy rates8
 Linezolid, 84.4% (credible interval: 76.6%–90.6%)
 Vancomycin, 74.7% (credible interval: 64.1%–83.5%)









ICER = dominated 
by Linezolid
Abbreviations: ICER, incremental cost effectiveness ratio; PICC, peripherally inserted central catheter; QALY, quality-adjusted life years.
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and intravenous daptomycin in the treatment of MRSA 
cSSTI.
In our conservative base-case analysis of equal efficacy, 
equal length of stay, and resource use, linezolid had lower 
total medical costs compared with vancomycin and dap-
tomycin therapy. Linezolid’s higher drug price was offset 
by lower outpatient medical costs, specifically the cost of 
OPAT, PICC utilization and complications, and laboratory 
monitoring for vancomycin. On the contrary, vancomycin 
had significantly lower drug prices, but they were offset by 
higher outpatient medical costs. Daptomycin was found to 
have higher drug prices, and being only intravenous, had 
greater outpatient medical costs due to OPAT. As a result, 
its aggregated costs made it more expensive compared with 
linezolid and vancomycin.
Results were similar when efficacy rates and length of 
stay data from clinical studies were incorporated into the 
model. Linezolid was cost-saving compared with the other 
two therapies when length of stay was adjusted to 7.6 days for 
linezolid and 8.9 days for vancomycin and daptomycin based 
on previously published study results.7 Likewise,  linezolid had 
lower total costs compared with vancomycin and daptomycin 
therapy when efficacy rates were adjusted based on results 
obtained from a Bayesian meta-analysis.8 In this scenario, 
linezolid had marginally higher QALY gains and when com-
bined with lower costs, made it a in dominant strategy.
Our outcomes were similar to results from several studies 
reported in the published medical literature, where linezolid 
had overall lower costs compared with vancomycin, mainly 
due to fewer inpatient days and ability to switch to an oral 
formulation.9,12,13,21–24,41,43,44
In contrast, one published cost-effectiveness analysis in 
2009 by Bounthavong and coworkers reported higher costs 
with linezolid than vancomycin in the treatment of MRSA 
cSSTI.20 The total direct costs for treatment with inpatient fol-
lowed by outpatient intravenous vancomycin was US$9,750, 
inpatient intravenous vancomycin followed by outpatient oral 
linezolid was US$10,018, inpatient intravenous vancomycin 
for the treatment duration was US$16,686, and intravenous 
inpatient linezolid followed by oral inpatient and then out-
patient linezolid was US$10,975.
There were several differences between our study and 
the 2009 study conducted by Bounthavong and coworkers.20 
First, although Bounthavong and coworkers mentioned 
nursing labor costs for OPAT, these costs were not included 
in their list of base-case costs. In comparison, our model 
included the cost of vancomycin OPAT either administered 
at home or at an infusion center. Second, Bounthavong and 
coworkers did not incorporate the cost of a PICC line for 
outpatient administration of vancomycin into their model. 
Evidence suggested that vancomycin should be administered 
through a central catheter to decrease the risk of phlebitis.45 
Last, hospital length of stay varied between our model and 
that by Bounthavong. In our base-case analysis, we used a 
4.5-day length of stay for all patients. This timeframe was 
chosen based on the average length of stay for patients with 
SSTI.16 In our second scenario, we used a 1-day shorter 
length of stay for linezolid- compared with vancomycin-
treated patients based on data from a published clinical 
study that evaluated linezolid and vancomycin treatment in 
patients with MRSA cSSTI.7 In contrast, Bounthavong used 
an approximately 2-day shorter inpatient stay for patients 
who received vancomycin rather than linezolid, a fact not 
supported by data in the published literature. Data from pub-
lished studies suggested a shorter hospital stay for patients 
received linezolid than vancomycin for complicated MRSA 
SSTI.7,9,11–15 A shorter length of hospital stay with linezolid 
compared with vancomycin therapy was evident even when 
there were no barriers to a vancomycin OPAT program.7 From 
data published by Bounthavong, a 2-day increase in hospital 
length of stay for linezolid-treated patients increased costs by 
approximately US$2,500 (unexplained in the article), much 
more than the cost difference between intravenous inpatient 
followed by outpatient vancomycin (US$9,750) and inpatient 
intravenous than oral linezolid followed by outpatient oral 
linezolid (US$10,975).
Recently, these authors published another cost-effective-
ness analysis using Bayesian methods and added daptomycin 
as a treatment comparator. They reported that linezolid was 
dominant (better outcomes, lower costs) compared with 
vancomycin and daptomycin when delivered in the inpatient 
setting.24 Our current analysis, which includes both inpatient 
and outpatient management of cSSTI, further added to the 
literature regarding potential cost aspects of vancomycin and 
daptomycin OPAT delivery.
As mentioned earlier, there were very few studies that 
have assessed the economic impact of daptomycin for the 
treatment of MRSA cSSTI. In addition to the study described 
above, a study conducted by Davis and colleagues in 2007 
compared daptomycin with vancomycin and reported the 
former to be more cost-effective.25 However, this study had 
a nonrandomized prospective data analytical design (and 
not cost-effectiveness), did not correct success rates for the 
imbalance in MRSA cases (daptomycin 42% MRSA versus 
75% MRSA in the vancomycin group, P , 0.001), and 
focused only on inpatient costs.
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What are the implications of our analysis? First, this 
analysis highlights the value of including an appropriate 
analysis timeframe to include the full treatment period. In 
our analysis, we included all relevant inpatient and outpatient 
costs for the treatment period. Second, this analysis shows 
the continuing shift of costs from the inpatient to outpa-
tient setting where some 20%–35% of costs were incurred, 
depending on drug used. Lastly, this analysis, similar to 
previously reported analyses,9,12,13,21–24 demonstrates that 
despite its higher acquisition cost, linezolid compared with 
vancomycin and daptomycin for the treatment of MRSA 
cSSTI has a more favorable economic profile from a US, 
third-party payer perspective.
Several limitations exist with this model, but are not uncom-
mon in economic modeling studies. Due to lack of available 
evidence, this model is partly based on expert opinion. Clearly, 
expert opinion is not the highest level of evidence. However, 
combining expert opinion with trial data and managed care 
resource utilization data allows estimation of the cost savings 
and cost-effectiveness of the considered antibiotics.
The impact of adverse events on both clinical and economic 
outcomes is hard to assess. In our model, adverse events were 
assigned to the vancomycin arm in the empiric but not defini-
tive phase of treatment. Whereas patients receiving empiric 
vancomycin followed by definitive linezolid had adverse 
event costs added in both the empiric and definitive treatment 
phases, those patients receiving empiric vancomycin followed 
by definitive vancomycin only had adverse event costs added 
during the empiric phase. This provided a slight cost advantage 
for vancomycin compared with linezolid therapy.
The assumption that second-line treatment is 100% 
effective is clearly a simplification of reality. However, this 
assumption was discussed and considered reasonable by 
clinical experts because there are no published efficacy data 
for second-line treatments in patients with MRSA cSSTI. 
This assumption was also used in a previously published 
model20 and required to avoid extrapolation of the time hori-
zon beyond 4 weeks. Nevertheless, we believe the base-case 
analysis remains conservative.
The assumption that no patients died during the 4-week 
model timeframe is also a simplification of reality.  However, 
evidence suggests that mortality rates are similar between 
patients with MRSA cSSTI treated with linezolid or 
 vancomycin.5 Therefore, costs due to mortality would be 
similar for both treatment arms and were not included, 
a decision not unique to our study.20
Lastly, the true cost of OPAT is not known. Outpatient 
infusion of intravenous antibiotics is a complex process. In a 
study designed to map out an OPAT program, six processes, 
67 sub-processes, and 217 possible failures were identified.46 
In the US, several different models for OPAT are utilized. 
Patients can travel to an infusion center for drug admin-
istration, or the patient, a caregiver, or a visiting nurse or 
other health care professional can administer the drug at the 
patient’s home.47 Obviously, the costs associated with these 
models will differ. In one study, reimbursement for vanco-
mycin OPAT primarily administered by the patient in their 
home ranged from US$103 to US$268 per day.29 Regardless 
of OPAT model utilized, all are more complex, costly, and 
time intensive than oral antibiotic administration.
Outpatient parenteral antibiotic therapy also requires 
patients to have intravenous access. There are numerous 
options for intravenous access, each associated with dif-
ferent costs and complications. We opted to include the 
cost of a PICC line into our model. In one study, more 
than 50% of patients receiving OPAT with vancomycin 
had a PICC line.32 Recommendations are for drugs with 
moderate phlebitis risk, such as vancomycin, to be admin-
istered through a central line.45 Regardless of intravenous 
catheter utilized, costs and complications associated with 
that catheter would be higher than those for patients not 
needing intravenous access.
Conclusion
This economic analysis is an update to a previously presented 
analysis, and it provides an important perspective on the 
inpatient and outpatient cost breakdown for the treatment of 
patients with cSSTI due to MRSA.48 Total treatment costs in the 
base-case analysis for patients with MRSA cSSTI were lower 
for linezolid than vancomycin and daptomycin therapy even 
though total drug acquisition costs were higher for  linezolid 
versus vancomycin. When looking specifically at the total 
outpatient costs in our analysis, a linezolid oral strategy was 
30%–50% less costly than OPAT with vancomycin or dapto-
mycin. Additional benefits could be realized if indirect costs 
were evaluated. Recent medical literature suggests that patients 
would prefer oral compared with intravenous administration 
when outcomes are similar in order to maintain work produc-
tivity and freedom of activities once they leave the hospital.49
OPAT is a reasonable option for patients well enough 
to leave the hospital but still needing intravenous antibiotic 
therapy. However, OPAT treatment guidelines state that this 
method of drug administration be reserved for cases where 
other routes of drug administration are not an option.42 With 
linezolid approved as an effective oral option for treat-
ing patients with MRSA, the economic value should be 
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 reconsidered by managed care plans evaluating outpatient 
treatment strategies for completing antibiotic therapies. 
Our results, like those from most previously published stud-
ies,9,12,13,21–24 show that the budget impact of linezolid com-
pared with vancomycin and daptomycin for the treatment of 
MRSA cSSTI is similar or cost saving when the total costs 
of inpatient and outpatient therapy are included.
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